Key result
Female sex shows no difference in long-term mortality compared to male sex after MIDCAB.
Why the study?
Does female sex increase the risk of all-cause long-term mortality in patients undergoing MIDCAB?
Population
350 consecutive patients undergoing MIDCAB at a single centre
Comparison
Females vs males
Design
Retrospective propensity score-matched cohort study
Follow-up
Median 19.0 years
Authors
Loading...
Supports equivalent long-term survival after MIDCAB in women and men; extends observational MIDCAB data but leaves open randomized confirmation.
Cohort (n=350)
No
Does female sex increase the risk of all-cause long-term mortality in patients undergoing MIDCAB?
Hazard Ratio: 0.8 (95% CI 0.38–1.7)
Absolute Event Rate: 12% vs 12%
p-value: p=0.560
MIDCAB provides equivalent long-term survival and perioperative safety for both women and men, challenging the historical view that female sex is an independent risk factor for adverse outcomes after surgical revascularization.
Amanov et al. (2026) conducted a cohort in Single-vessel or LAD-predominant coronary artery disease (n=350). Female sex vs. Male sex was evaluated on All-cause long-term mortality (HR 0.80, 95% CI 0.38-1.70, p=0.560). Female sex was not associated with an increased risk of long-term all-cause mortality after MIDCAB compared to male sex (adjusted HR 0.80, 95% CI 0.38-1.70, p=0.560).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: